<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838015</url>
  </required_header>
  <id_info>
    <org_study_id>8037</org_study_id>
    <nct_id>NCT04838015</nct_id>
  </id_info>
  <brief_title>Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS</brief_title>
  <acronym>SEP-RR</acronym>
  <official_title>Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple Sclerosis (MS) is a chronic, autoimmune, neurodegenerative disease; clinical events&#xD;
      are mainly attributed to myelin destruction and inflammatory of the central nervous system.&#xD;
&#xD;
      The diagnosis resides in clinical and radiological criteria according to 2017 McDonald&#xD;
      criteria.&#xD;
&#xD;
      Once the diagnosis of MS has been made, treatment should be initiated promptly, in order to&#xD;
      delay the onset of severe disability in the long-term, even more ocrelizumab are a treatment&#xD;
      of high efficacy.&#xD;
&#xD;
      Ocrelizumab is used as a first-line or second-line treatment in Relapsing Remitting MS (RRMS)&#xD;
      It is an anti-CD20 monoclonal antibody that provides rapid depletion of circulating CD20+ B&#xD;
      lymphocytes by complement-dependent cytotoxicity and antibody-dependent cellular&#xD;
      cytotoxicity.&#xD;
&#xD;
      The main objective is the retrospective evaluation of the impact of ocrelizumab on the&#xD;
      outcome of MS.&#xD;
&#xD;
      The secondary objective is the search of predictive factors of response to treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">November 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective study of the impact of ocrelizumab used in patients with multiple sclerosis</measure>
    <time_frame>Files analysed retrospectively from October 01, 2018 to November 31, 2020 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Major subject Suffering from relapsing-remitting MS&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Major subject (≥18 years old)&#xD;
&#xD;
          -  Suffering from relapsing-remitting MS (RRMS)&#xD;
&#xD;
          -  Supported in a neurology department at Strasbourg or Nancy University Hospital between&#xD;
             10/01/2018 and 11/31/2020.&#xD;
&#xD;
          -  Treated with ocrelizumab 600mg every 6 months during the period from 01/10/2018 to&#xD;
             01/05/2020.&#xD;
&#xD;
          -  Have had an M0, M3 / M6 and M12 MRI after initiation of treatment.&#xD;
&#xD;
          -  Subject not having expressed his opposition, after information, to the reuse of his&#xD;
             data for the purposes of this research&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Subject having expressed opposition to participating in the study&#xD;
&#xD;
          -  Primary progressive multiple sclerosis (MS-PP), secondarily progressive (MS-SP)&#xD;
&#xD;
          -  Subject not meeting all the inclusion criteria&#xD;
&#xD;
          -  Impossibility of providing the subject with enlightened information (difficulties in&#xD;
             understanding the subject, etc.)&#xD;
&#xD;
          -  Subjects under safeguard of justice&#xD;
&#xD;
          -  Subject under guardianship or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas COLLONGUES, MD</last_name>
    <phone>33 3 88 12 87 33</phone>
    <email>nicolas.collongues@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <phone>33 3 88 11 66 90</phone>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hautepierre Clinical Investigation Center - Strasbourg University Hospitals</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas COLLONGUES, MD</last_name>
      <phone>33 3 88 12 87 33</phone>
      <email>nicolas.collongues@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <phone>33 3 88 11 66 90</phone>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas COLLONGUES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaux TIBERI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kévin BIGAUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MEYER, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume MATHEY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MS-RR</keyword>
  <keyword>Ocrelizumab</keyword>
  <keyword>Switch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

